Document is current
Any future updates will be listed below
-
Authors
Ossima, Arnaud Nze
Brzustowski, Angélique
Paradis, Valérie
Van Beers, Bernard
Postic, Catherine
Laouénan, Cédric
Pol, Stanislas
Castéra, Laurent
Gautier, Jean-François
Czernichow, Sebastien
Vallet-Pichard, Anais
Larger, Etienne
Serfaty, Lawrence
Zins, Marie
Valla, Dominique
Zaleski, Isabelle Durand https://orcid.org/0000-0002-4078-1476
- License Information
-
More Information
Article History
Received: 28 August 2023
Accepted: 7 December 2023
First Online: 25 April 2024
Declarations
:
: This epidemiological study is based solely on data already collected. The CONSTANCES Cohort has obtained the authorization of the National Data Protection Authority (Commission nationale de l’informatique et des libertés—CNIL) on March 3, 2011 n°2011–067. This study was approved by CONSTANCES external scientific committee and conducted in accordance with the national data protection authority reference guideline (MR004).
: All authors gave their consent for publication.
: Pr Castera has received lectures fees from Echosens and Novo Nordisk and has served as a consultant for Echosens, Novo Nordisk, Madrigal, MSD, Pfizer and Sagimet. Pr Pol has received consulting and lecturing fees from Janssen, Gilead, MSD, Abbvie, Biotest, Shinogui, Viiv, LFB and grants from Bristol-Myers Squibb, Gilead, Roche and MSD without relation to this manuscript. Pr Durand-Zaleski has received consulting and lecturing fees from Amgen, BMS, MSD, Sanofi, Pfizer, Takeda without relation to this manuscript. Pr Czernichow has received consulting and lecturing fees from Lilly, Fresenius, Novartis, Novo Nordisk, BMS, Boehringer, Bariatek without relation to this manuscript. Pr Jean-François Gautier received consulting and lecture fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Gilead, Novo Nordisk, Pfizer, and Sanofi. Pr Valla has received lecture fees from Intercept. The other authors declare no conflict of interest.
